股本结构
单位：万股
| 公告日期 | 2026-08-14 | 2026-07-20 | 2026-08-14 | 2026-06-09 | 2026-05-15 | 2026-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1159.11 | 1149.46 | 1138.49 | 1081.91 | 1040.46 | 553.93 |
| 普通股本 | 1159.11 | 1149.46 | 1138.49 | 1081.91 | 1040.46 | 553.93 |
| 优先股 | 未披露 | 7.92 | 7.92 | 7.92 | 未披露 | 7.92 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-13 | 2026-07-17 | 2026-06-30 | 2026-06-08 | 2026-05-11 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-14 | 1159.11 | 未披露 | 定期报告 | 2026-08-13 |
| 2026-07-20 | 1149.46 | 7.92 | 定期报告 | 2026-07-17 |
| 2026-08-14 | 1138.49 | 7.92 |
更多>>
From March 31,2026 to June 30,2026
Issuance of common stock, net, in connection with restricted stock units vesting
Issuance of shares pursuant to At The Market Offering, net of issuance costs
Issuance of shares pursuant to pre-funded warrant exercises
Issuance of shares to non-employees
|
2026-06-30 |
| 2026-06-09 | 1081.91 | 7.92 | 定期报告 | 2026-06-08 |
| 2026-05-15 | 1040.46 | 未披露 | 定期报告 | 2026-05-11 |
| 2026-05-15 | 553.93 | 7.92 |
更多>>
From December 31,2025 to March 31,2026
Issuance of shares pursuant to pre-funded warrant exercises
Issuance of common stock, net, in connection with restricted stock units vesting
Issuance of shares to non-employees
|
2026-03-31 |
| 2026-03-31 | 553.93 | 未披露 | 定期报告 | 2026-03-27 |
| 2026-03-31 | 408.32 | 7.92 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of common stock pursuant to warrant exercises
Issuance of common stock pursuant to Registered Direct Offering, net of issuance costs
Issuance of common stock pursuant to Renovaro Extension Agreement
Issuance of common stock to non-employees as compensation
Issuance of common stock pursuant to At The Market Offering, net of issuance costs
Issuance of common stock pursuant to May 2025 private placement
Issuance of common stock pursuant to Yorkville SEPA commitment fee
Issuance of common stock pursuant to August 2025 private placement
Round up of fractional shares pursuant to reverse stock split
Issuance of shares and pre-funded warrants pursuant to October 2025 private placements, net of issuance costs
Issuance of common stock in connection with restricted stock units vesting
|
2025-12-31 |
| 2025-11-24 | 339.35 | 7.92 | 定期报告 | 2025-11-21 |
| 2025-11-14 | 339.35 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-10-27 | 350.14 | 未披露 | 定期报告 | 2025-10-24 |
| 2025-10-22 | 421.14 | 未披露 | 定期报告 | 2025-10-21 |
| 2025-10-15 | 413.89 | 未披露 | 定期报告 | 2025-10-13 |
| 2025-11-14 | 76.71 | 7.92 |
更多>>
a 1-for-15 reverse stock split of its issued and outstanding shares of common stock
From June 30, 2025 to September 30, 2025
Issuance of commitment fee shares pursuant to Yorkville SEPA
Round up of fractional shares pursuant to reverse stock split
Issuance of shares pursuant to warrant exercises
Issuance of shares pursuant to August 2025 private placement
Issuance of shares pursuant to At The Market Offering, net of issuance costs
|
2025-09-30 |
| 2025-09-02 | 1143.62 | 未披露 |
更多>>
Common Stock offered 543,544 shares by the company
|
2025-08-26 |
| 2025-08-18 | 1089.27 | 未披露 | 定期报告 | 2025-08-18 |
| 2025-08-13 | 1089.24 | 未披露 | 定期报告 | 2025-08-08 |
| 2025-07-18 | 1022.22 | 7.92 | 定期报告 | 2025-07-17 |
| 2025-08-13 | 959.67 | 7.92 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of shares to non-employees
Issuance of shares pursuant to At The Market Offering, net of issuance costs
Issuance of shares pursuant to May 2025 private placement
|
2025-06-30 |
| 2025-05-15 | 893.16 | 7.92 | 定期报告 | 2025-03-31 |
| 2025-03-31 | 893.16 | 未披露 | 定期报告 | 2025-03-26 |
| 2025-03-31 | 767.70 | 未披露 | 定期报告 | 2025-03-20 |
| 2025-02-19 | 720.97 | 未披露 |
更多>>
Common stock offered 363,336 shares by the company.
|
2025-02-19 |
| 2025-02-19 | 684.64 | 未披露 | 定期报告 | 2025-02-18 |
| 2025-01-13 | 666.72 | 7.92 | 定期报告 | 2025-01-06 |
| 2024-11-12 | 666.70 | 7.92 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs
|
2024-09-30 |
| 2024-08-15 | 666.72 | 7.92 | 定期报告 | 2024-08-13 |
| 2024-08-13 | 666.70 | 未披露 | 定期报告 | 2024-08-05 |
| 2024-07-29 | 506.01 | 未披露 |
更多>>
July 26, 2024 Predictive Oncology Inc. purchase 958,117 shares common stock.
|
2024-07-26 |
| 2024-08-13 | 570.89 | 7.92 | 定期报告 | 2024-06-30 |
| 2024-05-21 | 410.20 | 未披露 | 定期报告 | 2024-05-20 |
| 2024-05-14 | 410.18 | 未披露 | 定期报告 | 2024-05-10 |
| 2024-05-06 | 410.20 | 未披露 | 定期报告 | 2024-04-30 |
| 2024-03-28 | 406.29 | 7.92 |
更多>>
From December 31,2022 to December 31,2023
Shares issued to non-employees
Reverse stock split round up to whole shares
Share issuance to CFO for vesting of RSUs, net of repurchase to cover withholding tax
|
2023-12-31 |
| 2023-11-13 | 406.31 | 未披露 | 定期报告 | 2023-11-06 |
| 2023-11-13 | 403.33 | 7.92 | 定期报告 | 2023-09-30 |
| 2023-08-10 | 402.84 | 未披露 | 定期报告 | 2023-08-03 |
| 2023-08-10 | 400.63 | 7.92 | 定期报告 | 2023-06-30 |
| 2023-05-15 | 400.52 | 未披露 | 定期报告 | 2023-05-08 |
| 2023-04-20 | 397.99 | 未披露 |
更多>>
Predictive Oncology Inc. announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares.
|
2023-04-24 |
| 2023-04-20 | 7959.72 | 未披露 | 定期报告 | 2023-04-20 |
| 2023-03-29 | 7940.39 | 7.94 | 定期报告 | 2023-03-28 |
| 2023-03-29 | 7940.39 | 7.94 | 定期报告 | 2023-03-17 |
| 2023-03-21 | 7940.39 | 未披露 | 定期报告 | 2023-03-14 |
| 2023-03-21 | 7876.27 | 7.92 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of shares and warrants pursuant to May 2022 private placement, net
Shares issued pursuant to Equity Line
Share issuance to consultant and other
Vesting expense and option repricing
|
2022-12-31 |
| 2022-11-10 | 7875.35 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-10-18 | 7852.13 | 未披露 | 定期报告 | 2022-10-03 |
| 2022-11-10 | 7840.75 | 7.92 |
更多>>
From June 30,2022 to September 30,2022
Shares issued to consultant & other
Vesting expense
|
2022-09-30 |
| 2022-10-13 | 7838.89 | 7.92 | 定期报告 | 2022-09-20 |
| 2022-08-11 | 7838.43 | 未披露 | 定期报告 | 2022-08-05 |
| 2022-08-11 | 7815.51 | 7.92 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of shares and warrants pursuant to May 2022 Private Offering
Shares issued pursuant to equity line
Shares issued to consultant & other
|
2022-06-30 |
| 2022-05-18 | 7815.97 | 未披露 |
更多>>
1.Common stock offered by 8,162,720 shares.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 66,159,663 shares of common stock outstanding as of May 13, 2022
|
2022-05-18 |
| 2022-05-18 | 6615.97 | 未披露 | 定期报告 | 2022-05-13 |
| 2022-05-12 | 6615.27 | 未披露 | 定期报告 | 2022-05-03 |
| 2022-05-12 | 6590.65 | 7.92 |
更多>>
From December 31, 2021 to March 31, 2022
Shares issued pursuant to equity line
Shares issued to consultant & other
|
2022-03-31 |
| 2022-03-31 | 6591.10 | 未披露 | 定期报告 | 2022-03-24 |
| 2022-03-31 | 6561.46 | 7.92 |
更多>>
From December 31, 2020 to December 31, 2021
Shares issued pursuant to agreement with former CEO related to accrued interest
Issuance of shares and warrants pursuant to Shelf offerings, net
Issuance of shares and warrants pursuant to February 2021 private placement, net
Exercise of warrants
Shares issued pursuant to convertible debt
Issuance of shares and warrants pursuant to June 2021 direct placement, net
Shares issued pursuant to transition agreement with former CEO
Shares issued pursuant to Equity Line
Share issuance to consultant and other
Vesting expense and option repricing
|
2021-12-31 |
| 2021-11-10 | 6557.63 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-05 | 6558.09 | 未披露 | 定期报告 | 2021-10-26 |
| 2021-11-10 | 6545.75 | 7.92 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of warrants
Shares issued to consultant & other
Vesting expense, net of repurchases of common stock upon vesting of restricted stock units
|
2021-09-30 |
| 2021-08-11 | 6540.28 | 未披露 | 定期报告 | 2021-08-06 |
| 2021-08-11 | 6533.52 | 7.92 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of shares and warrants pursuant to June 2021 direct placement, net
Shares issued pursuant to transition agreement with former CEO
Shares issued pursuant to Equity Line
Shares issued to consultant & other
|
2021-06-30 |
| 2021-06-16 | 6533.97 | 未披露 |
更多>>
1.Common stock offered 15,520,911 shares.
|
2021-06-16 |
| 2021-05-12 | 4981.88 | 未披露 | 定期报告 | 2021-05-07 |
| 2021-04-28 | 4981.38 | 7.92 | 定期报告 | 2021-04-23 |
| 2021-05-12 | 4879.43 | 7.92 |
更多>>
From December 31, 2020 to March 31, 2021
Shares issued pursuant to CEO agreement related to accrued interest
Issuance of shares and warrants pursuant to Shelf offerings, net
Issuance of shares and warrants pursuant to February 2021 private placement, net
Exercise of warrants
Shares issued pursuant to convertible debt
Shares issued to consultant & other
|
2021-03-31 |
| 2021-03-15 | 4879.43 | 未披露 | 定期报告 | 2021-03-10 |
| 2021-03-15 | 4879.89 | 7.92 | 定期报告 | 2021-03-09 |
| 2021-02-16 | 3645.23 | 未披露 |
更多>>
1.Securities offered by the company 4,222,288 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 32,230,047 shares of common stock outstanding as of February 10, 2021.
|
2021-02-16 |
| 2021-02-12 | 3223.00 | 未披露 | 定期报告 | 2021-02-10 |
| 2021-01-29 | 3080.38 | 7.92 |
更多>>
1.Securities offered by the company 3,414,970 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 27,013,789 shares of common stock outstanding as of January 21, 2021.
|
2021-01-26 |
| 2021-01-25 | 2701.38 | 未披露 |
更多>>
1.Securities offered by the company 2,200,000 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 24,106,575 shares of common stock outstanding as of January 18, 2021.
|
2021-01-21 |
| 2021-01-21 | 2410.66 | 未披露 | 定期报告 | 2021-01-18 |
| 2021-01-12 | 2409.20 | 未披露 |
更多>>
1.Securities offered by the company 3,650,840 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 20,441,199 shares of common stock outstanding as of January 7, 2021.
|
2021-01-12 |
| 2021-01-12 | 2044.12 | 未披露 | 定期报告 | 2021-01-07 |
| 2021-01-12 | 2027.96 | 未披露 | 定期报告 | 2021-01-05 |
| 2021-03-15 | 1980.48 | 7.92 |
更多>>
From December 31, 2019 to December 31, 2020
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement
Inducement shares issued pursuant to promissory note extension
Issuance of shares and prefunded warrants pursuant to March 2020 private placement
Inducement shares issued pursuant to 2020 convertible debt and warrants
Shares issued pursuant to note conversions - bridge loan
Shares issued pursuant to series E preferred stock conversions
Shares issued pursuant to series D preferred stock conversions
Issuance of shares from prefunded warrant exercises
Issuance of shares pursuant to May 2020 offering, net
Shares issued in connection with asset purchase agreement
Exercise of warrants and issuance of new warrants June 2020, net
Exercise of warrants
Shares issued pursuant to Equity Line
Shares issued pursuant to convertible debt
Share issuance to consultant and other
|
2020-12-31 |
| 2020-11-16 | 1767.66 | 未披露 | 定期报告 | 2020-11-11 |
| 2020-11-03 | 1755.01 | 未披露 | 定期报告 | 2020-10-28 |
| 2020-11-16 | 1659.33 | 7.92 |
更多>>
From June 30, 2020 to September 30, 2020
Shares issued in connection with asset purchase agreement
Exercise of warrants
Share issuance to consultant and other
Shares issued pursuant to Equity Line
Director Compensation
|
2020-09-30 |
| 2020-09-15 | 1542.10 | 7.92 | 定期报告 | 2020-09-04 |
| 2020-08-13 | 1521.32 | 未披露 | 定期报告 | 2020-08-10 |
| 2020-07-29 | 1450.36 | 未披露 | 定期报告 | 2020-07-23 |
| 2020-07-14 | 1320.08 | 7.92 | 定期报告 | 2020-07-07 |
| 2020-08-13 | 1319.08 | 7.92 |
更多>>
From March 31, 2020 to June 30, 2020
Shares issued pursuant to series D preferred stock conversions
Shares issued pursuant to series E preferred stock conversions
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement
Issuance of shares from prefunded warrant exercises
Issuance of shares pursuant to May 2020 offering, net
Shares issued in connection with Asset Purchase Agreement
Exercise of warrants and issuance of new warrants June 2020, net
Director compensation
|
2020-06-30 |
| 2020-06-24 | 1190.56 | 7.92 | 定期报告 | 2020-06-15 |
| 2020-06-08 | 1064.82 | 未披露 | 定期报告 | 2020-06-05 |
| 2020-04-14 | 619.77 | 未披露 | 定期报告 | 2020-04-13 |
| 2020-06-08 | 585.27 | 357.95 |
更多>>
From December 31, 2019 to March 31, 2020
Shares issued pursuant to CEO exchange agreement
Inducement shares issued pursuant to promissory note extension
Issuance of shares and prefunded warrants pursuant to March 2020 private placement
Inducement shares issued pursuant to 2020 convertible debt and warrants
Shares issued pursuant to note conversions - bridge loan
Shares issued pursuant to series E preferred stock conversions
Shares issued pursuant to Equity Line
Shares issued to consultant and other
|
2020-03-31 |
| 2020-04-01 | 584.77 | 未披露 | 定期报告 | 2020-03-27 |
| 2020-04-01 | 405.67 | 357.95 |
更多>>
From December 31, 2018 to December 31, 2019
Stock issued for Helomics acquisition
Issuance of Series E preferred shares
Investment by CEO
Shares issued in forbearance agreement
Shares issued pursuant to S-3 public offering
Shares issued pursuant to note conversions - bridge loan
Shares issued pursuant to bridge loan agreement
Shares issued pursuant to promissory notes
Stock issued to extinguish debt as part of Helomics purchase consideration
Exercise of warrants
Inducement shares issued pursuant to equity line
Shares issued pursuant to equity line
Share issuance to investor relations consultant and other
|
2019-12-31 |
| 2019-12-10 | 392.50 | 未披露 | 定期报告 | 2019-12-03 |
| 2019-11-25 | 388.80 | 0.03 | 定期报告 | 2019-11-13 |
| 2019-10-28 | 388.80 | 未披露 |
更多>>
On October 25, 2019, the Certificate of Incorporation of Predictive Oncology Inc. (the “Company”) was amended to effect a reverse stock split of the outstanding shares of its common stock at a ratio of one-for-ten (1:10). The amendment was effective October 28, 2019; however, the reverse stock split will be effective for purposes of the stock market as of the opening of trading on October 29, 2019.
|
2019-10-29 |
| 2019-10-10 | 3783.30 | 未披露 | 定期报告 | 2019-10-04 |
| 2019-10-01 | 3149.75 | 未披露 | 定期报告 | 2019-09-27 |
| 2019-09-30 | 3125.89 | 0.03 | 定期报告 | 2019-09-23 |
| 2019-08-19 | 3125.89 | 未披露 | 定期报告 | 2019-08-13 |
| 2019-08-19 | 3097.48 | 357.93 |
更多>>
From January 1,2019 to June 30,2019
Stock issued for Helomics acquisition
Investment by CEO
Shares issued in forbearance agreement
Shares issued pursuant to S-3 public offering
Shares issued pursuant to note conversions - bridge loan
Stock issued to extinguish debt as part of Helomics purchase consideration
Exercise of warrants
|
2019-06-30 |
| 2019-05-15 | 3068.06 | 未披露 | 定期报告 | 2019-05-14 |
| 2019-05-15 | 1736.01 | 7.92 |
更多>>
From January 1, 2019 to March 31, 2019
Investment by CEO
Shares issued in forbearance agreement
Shares issued pursuant to S-3 public offering
Shares issued pursuant to note conversions – bridge loan
|
2019-03-31 |
| 2019-04-01 | 1579.26 | 未披露 | 定期报告 | 2019-03-26 |
| 2019-02-13 | 1433.65 | 未披露 | 定期报告 | 2019-02-12 |
| 2019-01-24 | 1416.99 | 未披露 | 定期报告 | 2019-01-23 |
| 2019-04-01 | 1409.17 | 7.92 |
更多>>
From December 31, 2017 to December 31, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment in Subsidiary pursuant to Helomics 20% acquisition
E Warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
Re-priced warrant exercise pursuant to 2016 private investment
Shares issued pursuant to a consultant contract @ $1.18 per share
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share
Shares issued as inducement for Bridge Loan
Shares issued to employee in lieu of bonus
|
2018-12-31 |
| 2018-12-26 | 1409.17 | 未披露 | 定期报告 | 2018-12-19 |
| 2018-12-07 | 1299.17 | 未披露 | 定期报告 | 2018-11-28 |
| 2018-11-14 | 1409.17 | 未披露 | 定期报告 | 2018-11-12 |
| 2018-10-29 | 1404.83 | 未披露 | 定期报告 | 2018-10-15 |
| 2018-11-14 | 1339.83 | 7.92 |
更多>>
From January 1, 2018 to September 30, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment pursuant to Helomics 20% acquisition
E Warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
Re-priced warrant exercise pursuant to 2016 private investment
Shares issued pursuant to a consultant contract @ $1.18 per share
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share
|
2018-09-30 |
| 2018-08-14 | 1339.83 | 未披露 | 定期报告 | 2018-08-12 |
| 2018-07-05 | 1083.33 | 未披露 | 定期报告 | 2018-07-05 |
| 2018-08-14 | 1208.94 | 7.92 |
更多>>
From January 1, 2018 to June 30, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment pursuant to Helomics 20% acquisition
E Warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
Re-priced warrant exercise pursuant to 2016 private investment
|
2018-06-30 |
| 2018-05-15 | 1180.41 | 7.92 |
更多>>
From December 31, 2017 to March 31, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment in subsidiary pursuant to Helomics 20% acquisition
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
|
2018-03-31 |
| 2018-04-02 | 1180.41 | 未披露 |
更多>>
In January 2018, the Company completed a firm commitment underwritten public offering of 2,900,000 Units at an offering price of $0.95 per Unit, with each Unit consisting of one share of the Company’s Common Stock and 0.3 of a Series E Warrant, with each whole Series E Warrant purchasing one share of common stock at an exercise price of $1.00 per whole share. On January 11, 2018, the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement Helomics issued 2,500,000 shares of its Series A Preferred Stock in exchange for 1,100,000 shares of Skyline’s common stock.On February 22, 2018, the Company completed a conversion of a portion of the principal amount of Notes owed by Helomics Holding Corporation and received an assignment of intellectual property. Immediately prior to the conversion, Helomics owed the Company $667,512.50.
|
2018-03-19 |
| 2018-04-02 | 694.33 | 72.71 |
更多>>
From December 31, 2016 to December 31, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the over-allotment agreement in the public offering
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement
Shares issued pursuant to consulting agreement
Shares issued at $1.58 per share to an investor relations consultant
Shares issued pursuant to a private placement
Preferred conversion to common shares pursuant to a private placement agreement
|
2017-12-31 |
| 2017-12-04 | 628.28 | 未披露 | 定期报告 | 2017-11-27 |
| 2017-08-11 | 623.28 | 7.92 |
更多>>
From December 31, 2016 to Auguest 11, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the overallotment agreement in the public offering
Reverse shares issued for escrow with GLG Pharma pursuant to termination agreement
Shares issued pursuant to consulting agreement
Shares issued pursuant to consulting agreement
|
2017-08-11 |
| 2017-08-14 | 618.94 | 7.92 |
更多>>
From December 31, 2016 to June 30, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the overallotment agreement in the public offering
Reverse shares issued for escrow with GLG Pharma pursuant to termination agreement
Shares issued pursuant to consulting agreement
|
2017-06-30 |
| 2017-05-15 | 618.94 | 未披露 | 定期报告 | 2017-05-12 |
| 2017-05-15 | 648.94 | 7.92 |
更多>>
From December 31, 2016 to March 31, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the overallotment agreement in the public offering
|
2017-03-31 |
| 2017-03-15 | 648.94 | 未披露 | 定期报告 | 2017-03-15 |
| 2017-03-15 | 456.44 | 7.92 |
更多>>
From December 31, 2015 to December 31, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for two options exercised at $65.75 per share
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series B warrant exercises per the tender offer exchange
Shares issued at $3.75 per share, to an investment banker per contractual agreement
Shares issued at $4.50 per share to former CEO per severance agreement
Shares issued at $4.50 per share, to investor relations consultant
Shares issued for escrow with GLG Pharma pursuant to the partnership and reseller agreement
Shares issued pursuant to the Registered Direct Offering , net
Corrections due to rounding for reverse split and DTCC increase
On October 27, 2016, Skyline Medical Inc. announces that the Company’s board of directors has unanimously approved a reverse split of the Company’s common stock at a ratio of 1-for-25. The reverse stock split will become effective as of the close of business on October 27, 2016, with anticipated trading on a post-split basis on NASDAQ commencing at the open of the stock market on October 28, 2016.
|
2016-12-31 |
| 2017-01-03 | 456.44 | 未披露 | 定期报告 | 2016-12-29 |
| 2016-12-09 | 456.21 | 未披露 | 定期报告 | 2016-11-30 |
| 2016-11-14 | 380.49 | 未披露 | 定期报告 | 2016-10-31 |
| 2016-11-14 | 340.49 | 7.92 |
更多>>
From December 31, 2015 to October 28, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for two options exercised at $65.75 per share
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series B warrant exercises per the tender offer exchange
Shares issued at $3.75 per share, to an investment banker per contractual agreement
Shares issued at $4.50 per share to former CEO per severance agreement
Shares issued at $4.50 per share to investor relations consultant
Corrections due to rounding for reverse split
On October 27, 2016, Skyline Medical Inc. announces that the Company’s board of directors has unanimously approved a reverse split of the Company’s common stock at a ratio of 1-for-25. The reverse stock split will become effective as of the close of business on October 27, 2016, with anticipated trading on a post-split basis on NASDAQ commencing at the open of the stock market on October 28, 2016.
|
2016-10-28 |
| 2016-09-23 | 8447.15 | 7.92 | 定期报告 | 2016-09-19 |
| 2016-08-09 | 8180.49 | 未披露 | 定期报告 | 2016-08-03 |
| 2016-08-12 | 7769.84 | 8.06 |
更多>>
from December 31, 2015 to June 30, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series B warrant exercises per the tender offer exchange
Shares issued at $0.15 per share, to an investment banker per contractual agreement
Shares issued at $0.18 per share, to former CEO per severance agreement
|
2016-06-30 |
| 2016-06-24 | 7636.58 | 未披露 | 定期报告 | 2016-06-17 |
| 2016-05-23 | 6615.96 | 未披露 | 定期报告 | 2016-05-19 |
| 2016-05-23 | 5325.95 | 69.05 |
更多>>
from December 31, 2015 to March 31, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for two options exercised at $2.63 per share
Shares issued for cashless warrant exercises per the break-up of the Unit from the 2015 public offering
|
2016-03-31 |
| 2016-03-16 | 4989.41 | 未披露 | 定期报告 | 2016-03-16 |
| 2016-04-01 | 3949.81 | 189.50 |
更多>>
Approximately 3,390,935 Series A Warrants have been exercised in cashless exercises as of March 11, 2016, resulting in the issuance of 34,053,653 shares of Common Stock.
|
2016-03-11 |
| 2016-03-16 | 520.64 | 189.50 |
更多>>
from December 31, 2014 to December 31, 2015
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $9.75 per share
Reduction in escrow account per settlement agreement
Shares issued for a note conversion at $2.90 per share
Shares issued for a note conversion at $2.96 per share
Shares issued for a note conversion at $2.91 per share
Shares issued for a note conversion at $2.77 per share
Shares issued for a note conversion at $2.25 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
Shares issued for a note conversion at $2.00 per share
Shares issued for a note conversion at $2.27283 per share
Shares issued for a note conversion at $2.0179 per share
Shares issued for a note conversion at $1.92417 per share
Shares issued for a note conversion at $1.8578 per share
Vesting Expense
Shares issued in public offering; net
Preferred stock conversion
Series A warrant exercise
|
2015-12-31 |
| 2015-11-13 | 520.34 | 189.50 |
更多>>
from December 31, 2014 to September 30, 2015
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $9.75 per share
Reduction in escrow account per settlement agreement
Shares issued for a note conversion at $2.90 per share
Shares issued for a note conversion at $2.96 per share
Shares issued for a note conversion at $2.91 per share
Shares issued for a note conversion at $2.77 per share
Shares issued for a note conversion at $2.25 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
Shares issued for a note conversion at $2.00 per share
Shares issued for a note conversion at $2.27283 per share
Shares issued for a note conversion at $2.0179 per share
Shares issued for a note conversion at $1.92417 per share
Shares issued for a note conversion at $1.8578 per share
Dividends as converted to common shares at $9.75 per share
Vesting Expense
Shares issued in public offering; net
Preferred stock conversion
|
2015-09-30 |
| 2015-08-28 | 520.89 | 未披露 | 定期报告 | 2015-08-26 |
| 2015-08-20 | 331.29 | 2.06 |
更多>>
from December 31, 2014 to June 30, 2015
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $9.75 per share
Reduction in escrow account per settlement agreement
Shares issued for a note conversion at $2.90 per share
Shares issued for a note conversion at $2.96 per share
Shares issued for a note conversion at $2.91 per share
Shares issued for a note conversion at $2.77 per share
Shares issued for a note conversion at $2.25 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
Shares issued for a note conversion at $2.27283 per share
Shares issued for a note conversion at $2.0179 per share
Shares issued for a note conversion at $2.00 per share
Shares issued for a note conversion at $1.92417 per share
Shares issued for a note conversion at $1.8578 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
|
2015-06-30 |
| 2015-07-20 | 309.28 | 2.06 |
更多>>
from December 31, 2013 to December 31, 2014
Shares issued for cashless warrant exercise at $15.00 per share
Shares issued for option exercise at $1.25 per share
Shares issued at $20.63 per share as Investor Relations compensation
Shares issued for an option exercise at $5.25 per share
Shares issued for cashless warrant exercise at $.75 per share
Shares issued for warrant exercise at $13.50 per share
Shares issued at $18.75 per share as Investor Relations compensation
Reduction in escrow account per settlement agreement
Shares issued for cashless warrant exercise at $7.50 per share
Shares issued for cashless warrant exercise at $5.63 per share
Shares issued for cashless warrant exercise at $12.75 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share
Shares issued for combined cashless and cash warrant exercise @ $11.25 per share
Shares issued to Investor Relations consultant exercisable at $11.25 per share
Shares issued to Investor Relations consultant exercisable at $18.75 per share
Shares issued for cashless warrant exercise at $13.50 per share
Shares issued for cashless warrant exercise at $9.75 per share
Shares issued for a cash warrant exercise at $5.63 per share
Shares issued for a note conversion at $6.68 per share
Shares issued for a note conversion at $5.85 per share
Shares issued for a note conversion at $5.03 per share
Shares issued for a note conversion at $5.14 per share
Shares issued for a note conversion at $5.00 per share
Shares issued for a note conversion at $5.26 per share
Shares issued for a note conversion at $5.95 per share
Shares issued into an escrow account per settlement agreement
Shares issued for a note conversion at $5.05 per share
Shares adjusted for rounding per reverse stock split
Issuance of Preferred stock
|
2014-12-31 |
| 2014-12-16 | 309.12 | 未披露 | 定期报告 | 2014-12-12 |
| 2014-11-12 | 302.18 | 未披露 | 定期报告 | 2014-11-03 |
| 2014-11-12 | 299.94 | 2.06 |
更多>>
From December 31, 2013 to October 27, 2014
Shares issued for cashless warrant exercise at $15.00 per share
Shares issued for option exercise at $1.25 per share
Shares issued at $20.63 per share as Investor Relations compensation
Shares issued for cashless warrant exercise at $12.75 per share
Shares issued for an option exercise at $5.25 per share
Shares issued for cashless warrant exercise at $.75 per share
Shares issued for warrant exercise at $13.50 per share
Shares issued at $18.75 per share as Investor Relations compensation
Reduction in escrow account per settlement agreement
Shares issued for cashless warrant exercise at $7.50 per share
Shares issued for cashless warrant exercise at $5.63 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share
Shares issued for combined cashless and cash warrant exercise @ $11.25 per share.
Issuance of Preferred stock
Shares issued to Investor Relations consultant exercisable at $11.25 per share
Shares issued to Investor Relations consultant exercisable at $18.75 per share
Shares issued for cashless warrant exercise at $13.50 per share
Shares issued for cashless warrant exercise at $9.75 per share
Shares issued for a cash warrant exercise at $5.63 per share
Shares issued for a note conversion at $6.68 per share
Shares issued for a note conversion at $5.85 per share
Shares issued for a note conversion at $5.03 per share
The Company filed a Certificate of Amendment effecting a 1:75 reverse stock split (the “Reverse Stock Split”) with the Secretary of State of the State of Delaware, which became effective under Delaware law as of October 24, 2014.
|
2014-10-27 |
| 2014-09-26 | 22380.91 | 未披露 | 定期报告 | 2014-08-15 |
| 2014-09-26 | 22287.00 | 2.06 |
更多>>
From December 31, 2013 to June 30, 2014
Shares issued for cashless warrant exercise at $.20 per share
Shares issued for option exercise at $.0167 per share
Shares issued at $.275 per share as Investor Relations compensation
Shares issued for an option exercise at $.07 per share
Shares issued for cashless warrant exercise at $.01 per share
Shares issued for warrant exercise at $.18 per share
Shares issued at $.25 per share as Investor Relations compensation
Reduction in escrow account per settlement agreement
Shares issued for cashless warrant exercise at $.10 per share
Shares issued for cashless warrant exercise at $.075 per share
Shares issued for cashless warrant exercise at $.17 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share
Shares issued for combined cashless and cash warrant exercise @ $.15 per share.
Issuance of Preferred stock
Shares issued to Investor Relations consultant exercisable at $.15 per share
Shares issued to Investor Relations consultant exercisable at $.25 per share
Shares issued for cashless warrant exercise at $.18 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share
|
2014-06-30 |
From March 31,2026 to June 30,2026
Issuance of common stock, net, in connection with restricted stock units vesting
Issuance of shares pursuant to At The Market Offering, net of issuance costs
Issuance of shares pursuant to pre-funded warrant exercises
Issuance of shares to non-employees
From December 31,2025 to March 31,2026
Issuance of shares pursuant to pre-funded warrant exercises
Issuance of common stock, net, in connection with restricted stock units vesting
Issuance of shares to non-employees
From December 31, 2024 to December 31, 2025
Issuance of common stock pursuant to warrant exercises
Issuance of common stock pursuant to Registered Direct Offering, net of issuance costs
Issuance of common stock pursuant to Renovaro Extension Agreement
Issuance of common stock to non-employees as compensation
Issuance of common stock pursuant to At The Market Offering, net of issuance costs
Issuance of common stock pursuant to May 2025 private placement
Issuance of common stock pursuant to Yorkville SEPA commitment fee
Issuance of common stock pursuant to August 2025 private placement
Round up of fractional shares pursuant to reverse stock split
Issuance of shares and pre-funded warrants pursuant to October 2025 private placements, net of issuance costs
Issuance of common stock in connection with restricted stock units vesting
a 1-for-15 reverse stock split of its issued and outstanding shares of common stock
From June 30, 2025 to September 30, 2025
Issuance of commitment fee shares pursuant to Yorkville SEPA
Round up of fractional shares pursuant to reverse stock split
Issuance of shares pursuant to warrant exercises
Issuance of shares pursuant to August 2025 private placement
Issuance of shares pursuant to At The Market Offering, net of issuance costs
Common Stock offered 543,544 shares by the company
From March 31, 2025 to June 30, 2025
Issuance of shares to non-employees
Issuance of shares pursuant to At The Market Offering, net of issuance costs
Issuance of shares pursuant to May 2025 private placement
Common stock offered 363,336 shares by the company.
From June 30, 2024 to September 30, 2024
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs
July 26, 2024 Predictive Oncology Inc. purchase 958,117 shares common stock.
From December 31,2022 to December 31,2023
Shares issued to non-employees
Reverse stock split round up to whole shares
Share issuance to CFO for vesting of RSUs, net of repurchase to cover withholding tax
Predictive Oncology Inc. announced that it is effecting a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares.
From December 31, 2021 to December 31, 2022
Issuance of shares and warrants pursuant to May 2022 private placement, net
Shares issued pursuant to Equity Line
Share issuance to consultant and other
Vesting expense and option repricing
From June 30,2022 to September 30,2022
Shares issued to consultant & other
Vesting expense
From March 31, 2022 to June 30, 2022
Issuance of shares and warrants pursuant to May 2022 Private Offering
Shares issued pursuant to equity line
Shares issued to consultant & other
1.Common stock offered by 8,162,720 shares.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 66,159,663 shares of common stock outstanding as of May 13, 2022
From December 31, 2021 to March 31, 2022
Shares issued pursuant to equity line
Shares issued to consultant & other
From December 31, 2020 to December 31, 2021
Shares issued pursuant to agreement with former CEO related to accrued interest
Issuance of shares and warrants pursuant to Shelf offerings, net
Issuance of shares and warrants pursuant to February 2021 private placement, net
Exercise of warrants
Shares issued pursuant to convertible debt
Issuance of shares and warrants pursuant to June 2021 direct placement, net
Shares issued pursuant to transition agreement with former CEO
Shares issued pursuant to Equity Line
Share issuance to consultant and other
Vesting expense and option repricing
From June 30, 2021 to September 30, 2021
Exercise of warrants
Shares issued to consultant & other
Vesting expense, net of repurchases of common stock upon vesting of restricted stock units
From March 31, 2021 to June 30, 2021
Issuance of shares and warrants pursuant to June 2021 direct placement, net
Shares issued pursuant to transition agreement with former CEO
Shares issued pursuant to Equity Line
Shares issued to consultant & other
1.Common stock offered 15,520,911 shares.
From December 31, 2020 to March 31, 2021
Shares issued pursuant to CEO agreement related to accrued interest
Issuance of shares and warrants pursuant to Shelf offerings, net
Issuance of shares and warrants pursuant to February 2021 private placement, net
Exercise of warrants
Shares issued pursuant to convertible debt
Shares issued to consultant & other
1.Securities offered by the company 4,222,288 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 32,230,047 shares of common stock outstanding as of February 10, 2021.
1.Securities offered by the company 3,414,970 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 27,013,789 shares of common stock outstanding as of January 21, 2021.
1.Securities offered by the company 2,200,000 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 24,106,575 shares of common stock outstanding as of January 18, 2021.
1.Securities offered by the company 3,650,840 shares of common stock.
2.The number of shares of common stock to be outstanding immediately before and immediately after this offering is based on 20,441,199 shares of common stock outstanding as of January 7, 2021.
From December 31, 2019 to December 31, 2020
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement
Inducement shares issued pursuant to promissory note extension
Issuance of shares and prefunded warrants pursuant to March 2020 private placement
Inducement shares issued pursuant to 2020 convertible debt and warrants
Shares issued pursuant to note conversions - bridge loan
Shares issued pursuant to series E preferred stock conversions
Shares issued pursuant to series D preferred stock conversions
Issuance of shares from prefunded warrant exercises
Issuance of shares pursuant to May 2020 offering, net
Shares issued in connection with asset purchase agreement
Exercise of warrants and issuance of new warrants June 2020, net
Exercise of warrants
Shares issued pursuant to Equity Line
Shares issued pursuant to convertible debt
Share issuance to consultant and other
From June 30, 2020 to September 30, 2020
Shares issued in connection with asset purchase agreement
Exercise of warrants
Share issuance to consultant and other
Shares issued pursuant to Equity Line
Director Compensation
From March 31, 2020 to June 30, 2020
Shares issued pursuant to series D preferred stock conversions
Shares issued pursuant to series E preferred stock conversions
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement
Issuance of shares from prefunded warrant exercises
Issuance of shares pursuant to May 2020 offering, net
Shares issued in connection with Asset Purchase Agreement
Exercise of warrants and issuance of new warrants June 2020, net
Director compensation
From December 31, 2019 to March 31, 2020
Shares issued pursuant to CEO exchange agreement
Inducement shares issued pursuant to promissory note extension
Issuance of shares and prefunded warrants pursuant to March 2020 private placement
Inducement shares issued pursuant to 2020 convertible debt and warrants
Shares issued pursuant to note conversions - bridge loan
Shares issued pursuant to series E preferred stock conversions
Shares issued pursuant to Equity Line
Shares issued to consultant and other
From December 31, 2018 to December 31, 2019
Stock issued for Helomics acquisition
Issuance of Series E preferred shares
Investment by CEO
Shares issued in forbearance agreement
Shares issued pursuant to S-3 public offering
Shares issued pursuant to note conversions - bridge loan
Shares issued pursuant to bridge loan agreement
Shares issued pursuant to promissory notes
Stock issued to extinguish debt as part of Helomics purchase consideration
Exercise of warrants
Inducement shares issued pursuant to equity line
Shares issued pursuant to equity line
Share issuance to investor relations consultant and other
On October 25, 2019, the Certificate of Incorporation of Predictive Oncology Inc. (the “Company”) was amended to effect a reverse stock split of the outstanding shares of its common stock at a ratio of one-for-ten (1:10). The amendment was effective October 28, 2019; however, the reverse stock split will be effective for purposes of the stock market as of the opening of trading on October 29, 2019.
From January 1,2019 to June 30,2019
Stock issued for Helomics acquisition
Investment by CEO
Shares issued in forbearance agreement
Shares issued pursuant to S-3 public offering
Shares issued pursuant to note conversions - bridge loan
Stock issued to extinguish debt as part of Helomics purchase consideration
Exercise of warrants
From January 1, 2019 to March 31, 2019
Investment by CEO
Shares issued in forbearance agreement
Shares issued pursuant to S-3 public offering
Shares issued pursuant to note conversions – bridge loan
From December 31, 2017 to December 31, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment in Subsidiary pursuant to Helomics 20% acquisition
E Warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
Re-priced warrant exercise pursuant to 2016 private investment
Shares issued pursuant to a consultant contract @ $1.18 per share
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share
Shares issued as inducement for Bridge Loan
Shares issued to employee in lieu of bonus
From January 1, 2018 to September 30, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment pursuant to Helomics 20% acquisition
E Warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
Re-priced warrant exercise pursuant to 2016 private investment
Shares issued pursuant to a consultant contract @ $1.18 per share
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share
From January 1, 2018 to June 30, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment pursuant to Helomics 20% acquisition
E Warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
Re-priced warrant exercise pursuant to 2016 private investment
From December 31, 2017 to March 31, 2018
Preferred conversion to common shares pursuant to private placement agreement
Shares issued pursuant to S-3 public offering
Investment in subsidiary pursuant to Helomics 20% acquisition
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share
Shares issued pursuant to S-3 public offering over-allotment option at $0.9497 exercise price per share
In January 2018, the Company completed a firm commitment underwritten public offering of 2,900,000 Units at an offering price of $0.95 per Unit, with each Unit consisting of one share of the Company’s Common Stock and 0.3 of a Series E Warrant, with each whole Series E Warrant purchasing one share of common stock at an exercise price of $1.00 per whole share. On January 11, 2018, the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement Helomics issued 2,500,000 shares of its Series A Preferred Stock in exchange for 1,100,000 shares of Skyline’s common stock.On February 22, 2018, the Company completed a conversion of a portion of the principal amount of Notes owed by Helomics Holding Corporation and received an assignment of intellectual property. Immediately prior to the conversion, Helomics owed the Company $667,512.50.
From December 31, 2016 to December 31, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the over-allotment agreement in the public offering
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement
Shares issued pursuant to consulting agreement
Shares issued at $1.58 per share to an investor relations consultant
Shares issued pursuant to a private placement
Preferred conversion to common shares pursuant to a private placement agreement
From December 31, 2016 to Auguest 11, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the overallotment agreement in the public offering
Reverse shares issued for escrow with GLG Pharma pursuant to termination agreement
Shares issued pursuant to consulting agreement
Shares issued pursuant to consulting agreement
From December 31, 2016 to June 30, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the overallotment agreement in the public offering
Reverse shares issued for escrow with GLG Pharma pursuant to termination agreement
Shares issued pursuant to consulting agreement
From December 31, 2016 to March 31, 2017
Shares issued pursuant to the public offering, net
Shares issued pursuant to the overallotment agreement in the public offering
From December 31, 2015 to December 31, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for two options exercised at $65.75 per share
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series B warrant exercises per the tender offer exchange
Shares issued at $3.75 per share, to an investment banker per contractual agreement
Shares issued at $4.50 per share to former CEO per severance agreement
Shares issued at $4.50 per share, to investor relations consultant
Shares issued for escrow with GLG Pharma pursuant to the partnership and reseller agreement
Shares issued pursuant to the Registered Direct Offering , net
Corrections due to rounding for reverse split and DTCC increase
On October 27, 2016, Skyline Medical Inc. announces that the Company’s board of directors has unanimously approved a reverse split of the Company’s common stock at a ratio of 1-for-25. The reverse stock split will become effective as of the close of business on October 27, 2016, with anticipated trading on a post-split basis on NASDAQ commencing at the open of the stock market on October 28, 2016.
From December 31, 2015 to October 28, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for two options exercised at $65.75 per share
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series B warrant exercises per the tender offer exchange
Shares issued at $3.75 per share, to an investment banker per contractual agreement
Shares issued at $4.50 per share to former CEO per severance agreement
Shares issued at $4.50 per share to investor relations consultant
Corrections due to rounding for reverse split
On October 27, 2016, Skyline Medical Inc. announces that the Company’s board of directors has unanimously approved a reverse split of the Company’s common stock at a ratio of 1-for-25. The reverse stock split will become effective as of the close of business on October 27, 2016, with anticipated trading on a post-split basis on NASDAQ commencing at the open of the stock market on October 28, 2016.
from December 31, 2015 to June 30, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering
Shares issued for cashless Series B warrant exercises per the tender offer exchange
Shares issued at $0.15 per share, to an investment banker per contractual agreement
Shares issued at $0.18 per share, to former CEO per severance agreement
from December 31, 2015 to March 31, 2016
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering
Shares issued for two options exercised at $2.63 per share
Shares issued for cashless warrant exercises per the break-up of the Unit from the 2015 public offering
Approximately 3,390,935 Series A Warrants have been exercised in cashless exercises as of March 11, 2016, resulting in the issuance of 34,053,653 shares of Common Stock.
from December 31, 2014 to December 31, 2015
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $9.75 per share
Reduction in escrow account per settlement agreement
Shares issued for a note conversion at $2.90 per share
Shares issued for a note conversion at $2.96 per share
Shares issued for a note conversion at $2.91 per share
Shares issued for a note conversion at $2.77 per share
Shares issued for a note conversion at $2.25 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
Shares issued for a note conversion at $2.00 per share
Shares issued for a note conversion at $2.27283 per share
Shares issued for a note conversion at $2.0179 per share
Shares issued for a note conversion at $1.92417 per share
Shares issued for a note conversion at $1.8578 per share
Vesting Expense
Shares issued in public offering; net
Preferred stock conversion
Series A warrant exercise
from December 31, 2014 to September 30, 2015
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $9.75 per share
Reduction in escrow account per settlement agreement
Shares issued for a note conversion at $2.90 per share
Shares issued for a note conversion at $2.96 per share
Shares issued for a note conversion at $2.91 per share
Shares issued for a note conversion at $2.77 per share
Shares issued for a note conversion at $2.25 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
Shares issued for a note conversion at $2.00 per share
Shares issued for a note conversion at $2.27283 per share
Shares issued for a note conversion at $2.0179 per share
Shares issued for a note conversion at $1.92417 per share
Shares issued for a note conversion at $1.8578 per share
Dividends as converted to common shares at $9.75 per share
Vesting Expense
Shares issued in public offering; net
Preferred stock conversion
from December 31, 2014 to June 30, 2015
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares at $9.75 per share
Reduction in escrow account per settlement agreement
Shares issued for a note conversion at $2.90 per share
Shares issued for a note conversion at $2.96 per share
Shares issued for a note conversion at $2.91 per share
Shares issued for a note conversion at $2.77 per share
Shares issued for a note conversion at $2.25 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
Shares issued for a note conversion at $2.27283 per share
Shares issued for a note conversion at $2.0179 per share
Shares issued for a note conversion at $2.00 per share
Shares issued for a note conversion at $1.92417 per share
Shares issued for a note conversion at $1.8578 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $9.75 per share
from December 31, 2013 to December 31, 2014
Shares issued for cashless warrant exercise at $15.00 per share
Shares issued for option exercise at $1.25 per share
Shares issued at $20.63 per share as Investor Relations compensation
Shares issued for an option exercise at $5.25 per share
Shares issued for cashless warrant exercise at $.75 per share
Shares issued for warrant exercise at $13.50 per share
Shares issued at $18.75 per share as Investor Relations compensation
Reduction in escrow account per settlement agreement
Shares issued for cashless warrant exercise at $7.50 per share
Shares issued for cashless warrant exercise at $5.63 per share
Shares issued for cashless warrant exercise at $12.75 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share
Shares issued for combined cashless and cash warrant exercise @ $11.25 per share
Shares issued to Investor Relations consultant exercisable at $11.25 per share
Shares issued to Investor Relations consultant exercisable at $18.75 per share
Shares issued for cashless warrant exercise at $13.50 per share
Shares issued for cashless warrant exercise at $9.75 per share
Shares issued for a cash warrant exercise at $5.63 per share
Shares issued for a note conversion at $6.68 per share
Shares issued for a note conversion at $5.85 per share
Shares issued for a note conversion at $5.03 per share
Shares issued for a note conversion at $5.14 per share
Shares issued for a note conversion at $5.00 per share
Shares issued for a note conversion at $5.26 per share
Shares issued for a note conversion at $5.95 per share
Shares issued into an escrow account per settlement agreement
Shares issued for a note conversion at $5.05 per share
Shares adjusted for rounding per reverse stock split
Issuance of Preferred stock
From December 31, 2013 to October 27, 2014
Shares issued for cashless warrant exercise at $15.00 per share
Shares issued for option exercise at $1.25 per share
Shares issued at $20.63 per share as Investor Relations compensation
Shares issued for cashless warrant exercise at $12.75 per share
Shares issued for an option exercise at $5.25 per share
Shares issued for cashless warrant exercise at $.75 per share
Shares issued for warrant exercise at $13.50 per share
Shares issued at $18.75 per share as Investor Relations compensation
Reduction in escrow account per settlement agreement
Shares issued for cashless warrant exercise at $7.50 per share
Shares issued for cashless warrant exercise at $5.63 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share
Shares issued for combined cashless and cash warrant exercise @ $11.25 per share.
Issuance of Preferred stock
Shares issued to Investor Relations consultant exercisable at $11.25 per share
Shares issued to Investor Relations consultant exercisable at $18.75 per share
Shares issued for cashless warrant exercise at $13.50 per share
Shares issued for cashless warrant exercise at $9.75 per share
Shares issued for a cash warrant exercise at $5.63 per share
Shares issued for a note conversion at $6.68 per share
Shares issued for a note conversion at $5.85 per share
Shares issued for a note conversion at $5.03 per share
The Company filed a Certificate of Amendment effecting a 1:75 reverse stock split (the “Reverse Stock Split”) with the Secretary of State of the State of Delaware, which became effective under Delaware law as of October 24, 2014.
From December 31, 2013 to June 30, 2014
Shares issued for cashless warrant exercise at $.20 per share
Shares issued for option exercise at $.0167 per share
Shares issued at $.275 per share as Investor Relations compensation
Shares issued for an option exercise at $.07 per share
Shares issued for cashless warrant exercise at $.01 per share
Shares issued for warrant exercise at $.18 per share
Shares issued at $.25 per share as Investor Relations compensation
Reduction in escrow account per settlement agreement
Shares issued for cashless warrant exercise at $.10 per share
Shares issued for cashless warrant exercise at $.075 per share
Shares issued for cashless warrant exercise at $.17 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share
Shares issued for combined cashless and cash warrant exercise @ $.15 per share.
Issuance of Preferred stock
Shares issued to Investor Relations consultant exercisable at $.15 per share
Shares issued to Investor Relations consultant exercisable at $.25 per share
Shares issued for cashless warrant exercise at $.18 per share
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share